These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 28195943)

  • 21. Long term evaluation of flecainide acetate in supraventricular tachyarrhythmias.
    Mary-Rabine L; Telerman M
    Acta Cardiol; 1988; 43(1):37-48. PubMed ID: 3132008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of tachycardiac disorders of the heart rhythm by beta-receptor block of the atrioventricular tissue].
    Bender F; Kojima N; Reploh HD; Oelmann G
    Med Welt; 1966 May; 20():1120-3. PubMed ID: 5984492
    [No Abstract]   [Full Text] [Related]  

  • 23. Wide Complex Tachycardia in a Patient With a History of Atrial Fibrillation.
    Hegde S; Kumar V
    JAMA Intern Med; 2016 Mar; 176(3):386-8. PubMed ID: 26784121
    [No Abstract]   [Full Text] [Related]  

  • 24. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation.
    Freemantle N; Lafuente-Lafuente C; Mitchell S; Eckert L; Reynolds M
    Europace; 2011 Mar; 13(3):329-45. PubMed ID: 21227948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical trials of flecainide acetate in the management of supraventricular arrhythmias.
    Camm AJ; Bashir Y
    Cardiologia; 1990 Mar; 35(3):193-7. PubMed ID: 2123129
    [No Abstract]   [Full Text] [Related]  

  • 26. Unusual Wide Complex Tachycardia During Rhythm Control for Atrial Fibrillation.
    Banavalikar B; Shenthar J; Padmanabhan D
    Circulation; 2018 Jul; 138(5):537-539. PubMed ID: 30571524
    [No Abstract]   [Full Text] [Related]  

  • 27. [The use of digitalis glycosides in atrial fibrillation].
    Knez A; Haberl R; Steinbeck G
    Z Kardiol; 1994; 83 Suppl 5():71-3. PubMed ID: 7846948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term safety and efficacy of flecainide in the treatment of supraventricular tachyarrhythmias: the United States experience. The Flecainide Supraventricular Tachyarrhythmia Investigators.
    Anderson JL
    Am J Cardiol; 1992 Aug; 70(5):11A-17A; discussion 17A-18A. PubMed ID: 1509993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Encainide versus flecainide in the treatment of chronic resistant paroxysmal atrial tachyarrhythmias.
    Coumel P
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():579-84. PubMed ID: 2125836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brugada-type ECG pattern in patients treated with oral flecainide for lone atrial fibrillation: is there any clinical implication?
    Letsas KP; Weber R; Arentz T; Kalusche D
    Hellenic J Cardiol; 2009; 50(4):338-9. PubMed ID: 19622506
    [No Abstract]   [Full Text] [Related]  

  • 31. Paranoid psychosis and myoclonus: flecainide toxicity in renal failure.
    Ting SM; Lee D; Maclean D; Sheerin NS
    Cardiology; 2008; 111(2):83-6. PubMed ID: 18376118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flecainide: Electrophysiological properties, clinical indications, and practical aspects.
    Paolini E; Stronati G; Guerra F; Capucci A
    Pharmacol Res; 2019 Oct; 148():104443. PubMed ID: 31493514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Documentation of acute rise in ventricular capture thresholds associated with flecainide acetate.
    Fornieles-Pérez H; Montoya-García M; Levine PA; Sanz O
    Pacing Clin Electrophysiol; 2002 May; 25(5):871-2. PubMed ID: 12049386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Flecainide acetate for the treatment of atrial and ventricular arrhythmias.
    Apostolakis S; Oeff M; Tebbe U; Fabritz L; Breithardt G; Kirchhof P
    Expert Opin Pharmacother; 2013 Feb; 14(3):347-57. PubMed ID: 23294160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Severe cardiac toxicity following alcohol intake in a patient using therapeutic dose of propafenone.
    Bayram Z; Güner A; Doğan C; Yılmaz F; Özdemir N
    Turk Kardiyol Dern Ars; 2017 Dec; 45(8):752-754. PubMed ID: 29226898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The limitations of anti-arrhythmic drug therapy.
    Shimomura K; Ohe T
    Jpn Circ J; 1983 Jan; 47(1):153-7. PubMed ID: 6827772
    [No Abstract]   [Full Text] [Related]  

  • 37. Analysis of heart rate variability in a patient with paroxysmal atrial fibrillation.
    van den Berg MP; Haaksma J; Brouwer J; Crijns HJ; Lie KI
    Eur Heart J; 1995 Dec; 16(12):2011-2. PubMed ID: 8682048
    [No Abstract]   [Full Text] [Related]  

  • 38. [Pharmacogenetic study of the response to flecainide and propafenone in patients with atrial fibrillation].
    Martínez-Sellés M; Castillo I; Montenegro P; Martín ML; Almendral J; Sanjurjo M
    Rev Esp Cardiol; 2005 Jun; 58(6):745-8. PubMed ID: 15970126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation.
    Aliot E; Capucci A; Crijns HJ; Goette A; Tamargo J
    Europace; 2011 Feb; 13(2):161-73. PubMed ID: 21138930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iatrogenic Flecainide toxicity.
    Bond R; Augustine D; Walker S
    Heart; 2010 Dec; 96(24):2048-9. PubMed ID: 20736205
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.